No Data
No Data
No Data
China Briefing HK Stock Investment Journal|July 2nd
Hong Kong stock investment diary | July 2, 2024
Zhitoon Hong Kong Stock Investment Diary | July 1
Hong Kong Stock Investment Journal | July 1, 2024
Understanding the Ark Pharmacy (6086.HK) IPO at a glance.
Fangzhou Health (06086.HK) officially launched its IPO on June 28th. The company plans to sell 23.8 million shares globally, 2.38 million shares in Hong Kong, and 21.42 million shares internationally, with an additional 15% over-allotment option. Citigroup and Agricultural Bank of China International are the joint sponsors. The expected date for the shares to start trading on the main board of the Hong Kong Stock Exchange is July 9th, 2024. Let's take a closer look at Fangzhou Health (6086.HK)'s IPO situation.
New share announcement | The largest online chronic disease management platform, Ark Pharmacy (06086), will begin to solicit shares today and is expected to be listed on July 9th.
On June 28, 2024 to July 4, 2024, Jianke Ark (06086) will be listed, with a planned global offering of 23.8 million shares, of which 10% will be offered in Hong Kong and 90% will be offered internationally, with an additional 15% over-allotment option. The offering price per share is HKD 7.6-8.36, and each lot is 500 shares. The expected shares will start trading on the Stock Exchange of Hong Kong on July 9, 2024 (Tuesday) at 9:00 am.
Ark Pharmacy (06086.HK) plans to issue 23.8 million shares globally and is expected to be listed on July 9.
On June 28, Gelonghui announced that Arkpharmark (06086.HK) plans to issue a total of 23.8 million shares globally, with 2.38 million shares sold in Hong Kong, 21.42 million shares sold internationally, and an additional 15% over-allotment option. From June 28 to July 4, 2024, the company will be open for subscription, with the pricing date expected to be July 5. The sale price will be HKD 7.60-8.36 per share, with a trading unit of 500 shares per hand. Citigroup and Agricultural Bank of China International are joint sponsors. The expected listed date is July 9, 2024, on the main board of the Hong Kong Stock Exchange. According to data from Zhuoshi Consulting, the company had a flat performance in 2023.
No Data